Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity

Description

The major objective of this project is to examine whether daily consumption of milk polar lipids (MPLs) influences cardiometabolic risk factors.

Conditions

Dyslipidemias, Obesity

Talk to us

Study Overview

On this page

Study Details

Study overview

The major objective of this project is to examine whether daily consumption of milk polar lipids (MPLs) influences cardiometabolic risk factors.

Evaluation of Milk Polar Lipids on Lipoprotein Metabolism, Inflammation, and Gut Microbiota in Dyslipidemic Adults With Abdominal Obesity

Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity

Condition
Dyslipidemias
Intervention / Treatment

-

Contacts and Locations

Storrs

University of Connecticut, Storrs, Connecticut, United States, 06269

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * LDL-C ≥ 130 mg/dL
  • * Waist circumference ≥ 88 cm for women, ≥ 102 cm for men
  • * Aged 18 to 70 years
  • * Renal disease
  • * Liver disease
  • * Diabetes
  • * Heart disease
  • * Stroke
  • * Cancer
  • * Eating disorders
  • * Thyroid disease
  • * Gut-associated pathologies
  • * Autoimmune diseases
  • * Chronic inflammatory diseases
  • * Scleroderma
  • * Gallbladder disease
  • * Blood clotting disorders
  • * Intravenous drug use
  • * Fasting plasma/serum triglycerides \>500 mg/dL
  • * Fasting plasma/serum glucose \>126 mg/d
  • * Weight changes \>10% over last 4 weeks
  • * Oral antibiotics use up to 1 month prior to and during study
  • * Allergy or intolerance to milk products
  • * Taking lipid-lowering medications (e.g., statins, fibrates)
  • * Taking anti-inflammatory medications (e.g., corticosteroids)
  • * Taking medications which primarily affect blood clotting (e.g., warfarin).

Ages Eligible for Study

18 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Connecticut,

Study Record Dates

2025-12